Advances in Multiple Myeloma Treatment: CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates Evolving in Approved & Clinical Stages

June 28, 2026

Myeloma Crowd USA

Overview

An article summarizing the latest advancements in multiple myeloma treatment highlights the diversification of approved and investigational approaches, including CAR-T cell therapies, bispecific T-cell engagers, and antibody-drug conjugates. Real-world evidence for approved CAR-T therapies such as Kymriah, Yescarta, Breyanzi, Abecma, Carvykti, and Tecartus is accumulating, with reports of new indications and commercialization progress, significantly expanding treatment options for patients.

In Depth

Key Findings

The field of multiple myeloma (MM) treatment has seen remarkable progress in recent years, with several innovative approaches—including CAR-T cell therapies, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs)—continuing to evolve, both approved and in investigational stages. These novel therapeutic modalities offer renewed hope for patients with relapsed and refractory multiple myeloma.

Technical / Clinical Details

For CAR-T cell therapies, real-world evidence for approved products like Kymriah, Yescarta, Breyanzi, Abecma, Carvykti, and Tecartus is continuously accumulating. This data is crucial for a deeper understanding of the efficacy, safety profiles, and durability of CAR-T therapies in specific patient populations. For instance, Carvykti (cilta-cel) has established its clinical value by demonstrating high response rates and deep responses in patients with relapsed/refractory multiple myeloma. Furthermore, the commercialization of these CAR-T therapies is advancing through expanded indications and improved manufacturing capabilities. BiTEs represent a new class of agents that activate the patient’s own immune system by simultaneously targeting cancer cells and T cells; several candidates are in development for multiple myeloma. ADCs, which combine specific antibodies with potent cytotoxic drugs, are also showing promising results in clinical trials as an approach to efficiently eliminate cancer cells.

Background & Context

Multiple myeloma is an incurable blood cancer affecting plasma cells, and many patients become treatment-resistant over time. Given the limited efficacy of conventional chemotherapy, proteasome inhibitors, and immunomodulatory drugs, there has been a strong demand for innovative therapies. The advent of new modalities like CAR-T therapies, BiTEs, and ADCs is fundamentally transforming the multiple myeloma treatment paradigm. These therapies focus on new targets, such as BCMA (B-cell maturation antigen), in addition to traditional molecular targets, reflecting deep biological understanding and technological innovation.

Strategic Significance & Outlook

Multiple myeloma treatment is expected to continue its rapid evolution. Approved CAR-T therapies are expanding their indications, with considerations for use in earlier lines of treatment. The pipelines for BiTEs and ADCs are also robust, and many more agents are expected to transition from clinical trials to market. Research into combining and optimizing these novel therapies is also advancing, and personalized treatment strategies tailored to patient conditions and disease characteristics are anticipated to significantly improve the survival and quality of life for multiple myeloma patients. Real-world data will continue to play a crucial role in evaluating the long-term outcomes of these therapies and informing clinical guidelines.

Source: https://www.myeloma.org/blog/may-june-2026-whats-new-myeloma

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.